Nedd8 activating enzyme e1 inhibitor tas4464

Drug Overview

NEDD8 activating enzyme E1 inhibitor TAS4464 (also known as TAS4464) is an investigational, small-molecule inhibitor of the NEDD8-activating enzyme (NAE), the first enzyme in the neddylation pathway. Neddylation is a specific type of protein modification that is critical for the activation of Cullin-RING Ligases (CRLs), the largest family of E3 ubiquitin ligases. By inhibiting NAE, TAS4464 prevents the activation of CRLs, leading to the accumulation of their substrate proteins many of which are key regulators of cell growth, DNA repair, and apoptosis.

In the clinical landscape of March 2026, TAS4464 is recognized as a potent “proteostasis” inhibitor. Unlike proteasome inhibitors (like bortezomib) that block the final “garbage disposal” of the cell, TAS4464 blocks a specific “upstream” signaling event that tells the cell which proteins to dispose of. This targeted approach aims to overwhelm cancer cells with a build-up of proteins that trigger cell cycle arrest and death, making it a promising candidate for both hematologic malignancies (like multiple myeloma) and advanced solid tumors.

• Generic Name: NEDD8-activating enzyme E1 inhibitor TAS4464.
• Code Name: TAS4464.
• Drug Class: NAE Inhibitor; Protein Degradation Modulator.
• Mechanism: Irreversible inhibition of the NEDD8-activating enzyme (NAE), blocking CRL-mediated protein degradation.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, TAS4464 is not FDA-approved. It has been evaluated in several Phase 1 and Phase 2 trials, both as a single agent and in combination with other therapies.

What Is It and How Does It Work? (Mechanism of Action)

TAS4464 targets a biological “on/off switch” for a major class of protein-degrading enzymes in the cell.

The Neddylation Pathway

Neddylation is the process of attaching a small protein called NEDD8 to a target protein. In cancer cells, this process is often “hyper-activated” to help the tumor get rid of proteins that would normally stop its growth.

• NAE Inhibition: TAS4464 binds to the NAE enzyme (specifically the E1 enzyme) and prevents it from activating NEDD8.
• CRL Inactivation: Without activated NEDD8, the Cullin-RING Ligases (CRLs) cannot be “turned on.”

Molecular “Gridlock.”

When CRLs are turned off, their normal target proteins begin to accumulate to toxic levels.

1. DNA Damage Response: Proteins like CDT1 accumulate, leading to “over-replication” of DNA and severe DNA damage.
2. Cell Cycle Blockade: Proteins like p27 and p21 accumulate, which tells the cell to stop dividing immediately.
3. Pro-Apoptotic Stress: The build-up of these proteins causes massive “ER stress,” which ultimately triggers the cell to commit suicide (apoptosis).
4. NF-κ (Kappa)B Inhibition: TAS4464 also prevents the degradation of Iκ (Kappa)B, which keeps the NF-κ (Kappa)B survival pathway “turned off,” making cancer cells more vulnerable to other treatments.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for TAS4464.

Clinical research through 2026 has primarily focused on:

• Relapsed or Refractory Multiple Myeloma: Evaluated in patients who have already failed treatment with proteasome inhibitors and IMiDs.
• Acute Myeloid Leukemia (AML): Investigated as a way to “prime” leukemia cells to be more sensitive to chemotherapy.
• Advanced Solid Tumors: Studied in patients with metastatic cancers who have exhausted standard-of-care options.
• B-Cell Lymphomas: Evaluated in Phase 1 trials for various aggressive lymphoma subtypes.

Dosage and Administration Protocols

As an investigational drug, TAS4464 dosing is strictly determined by clinical trial protocols.

Clinical Efficacy and Research Results

As of early 2026, results from Phase 1 and early Phase 2 trials (such as the TAS4464-101 and TAS4464-102 studies) have provided significant insights:

• Biological Activity: Clinical data showed that TAS4464 effectively reduced the levels of “neddylated Cullins” in the blood and bone marrow, proving that the drug was successfully hitting its biological target.
• Response Rates: In early trials for multiple myeloma, several patients achieved a “partial response” or “stable disease,” even after multiple prior lines of therapy.
• Hepatotoxicity Challenges: A major finding in recent trials (2024–2025) was the occurrence of treatment-induced liver injury (hepatotoxicity) at higher dose levels, which has led to more careful dose-selection strategies in current studies.

Safety Profile and Side Effects

TAS4464 has a unique side effect profile related to its effect on protein regulation.

Common Side Effects (>20%):

• Hepatotoxicity: Elevation in liver enzymes (ALT/AST) and bilirubin. This is the most significant dose-limiting toxicity.
• Gastrointestinal: Nausea, vomiting, and diarrhea.
• Fatigue: General systemic tiredness reported by many patients.
• Hematologic: Anemia, neutropenia, and thrombocytopenia (low platelets).

Serious Risks:

• Severe Liver Injury: Potential for severe, drug-induced liver damage that may require stopping the treatment.
• Infusion Reactions: Fever, chills, or low blood pressure during the IV drip.
• Nephrotoxicity: Rare reports of changes in kidney function, requiring regular monitoring of creatinine levels.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, TAS4464 is being used to study “Proteostasis in Stem Cell Niches.” Researchers are investigating how inhibiting NAE affects the “longevity” of healthy hematopoietic stem cells. In 2026, there is also intense focus on “Synergistic Protein Degradation.” Scientists are exploring if TAS4464 can be combined with PROTACs (Proteolysis Targeting Chimeras) to achieve a “double-hit” on the cancer cell’s protein management system. Furthermore, studies are exploring if TAS4464 can help “overcome resistance” in tumors that have become insensitive to standard proteasome inhibitors.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Liver Function Tests (LFTs): Baseline and weekly monitoring of liver enzymes is mandatory.
• Baseline CBC: To check white blood cell and platelet levels.
• Heart Rhythm Assessment: Some trials require a baseline EKG to monitor for any changes in the heart’s electrical activity.

“Do’s and Don’ts” List:

• DO report any signs of yellowing skin or eyes (jaundice) or dark-colored urine immediately, as these are signs of liver stress.
• DO drink plenty of fluids on the day of and the day after your infusion to help protect your kidneys.
• DON’T take any new medications, including herbal supplements like St. John’s Wort, without consulting your oncologist, as they may interact with the liver enzymes that process TAS4464.
• DON’T ignore persistent nausea or diarrhea; your oncology team may need to adjust your dose or provide anti-nausea medication.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. TAS4464 is an investigational agent and is not approved by the U.S. FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.